

A photograph of a modern industrial factory floor. In the foreground, there are several large, white and grey industrial machines, likely injection molding presses. One machine has 'ELEKTRON 200' written on it, and another further back has 'ELEKTRON 110'. The machines are surrounded by stacks of green plastic crates, some of which are covered with clear plastic wrap. The ceiling is high with numerous square fluorescent light fixtures. A yellow overhead crane is visible in the background. The overall scene depicts a busy manufacturing environment.

Shaily Engineering Plastics Limited

Result Update Presentation
Q1FY18
September 2017



Shaily Engineering
Plastics Limited

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Shaily Engineering Plastics Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Q1FY18 - Financial Performance



Order inflow in Q1FY18



❑ New Business Confirmation

- Domestic FMCG major (new customer) for manufacture of packaging for one of their flagship products
- Pen injector order confirmation received in last quarter now extended for US markets
- Large domestic pharma company – order confirmation received for development of disposable insulin pen

❑ Business Update




- Ramp up in sales seen from auto ancillary company
- Improvement in sales seen in Corvi from Q3

❑ Commercialization from earlier Business confirmations




- Home furnishing major – Order confirmation received in Q3FY17, part commercial shipments started. Balance SKU's shipments to start by end Q2FY18/early Q3FY18
- Launched premium insulin pen for global pharma company for global markets
- Skin care device – development completed and samples submitted to customer for approval
- Derma applicator – development completed and samples submitted to customer for approval

Key Highlights – Q1FY18

(Rs. Cr.)




(Rs. Cr.)



**Cash PAT includes PAT & Depreciation*


Machine Utilization – Across Plants



...Focusing on higher value add products

Volume of Polymers Processed

Volume in Tonnes




...Increase in basket of product offering and quantity


*Volume in Tonnes

Witnessing Tailwinds

Machine Utilization (%)




Volumes of Polymers Processed (Tons)




Revenue Analysis - Domestic Vs. Exports

Q1FY17 - Revenue
Sales



■ Foreign ■ Domestic

Q1FY18 - Revenue
Sales



■ Foreign ■ Domestic



Quarterly Income Statement

Particulars in Rs. Crs	Q1FY18	Q1FY17	YoY %
Total Revenue#	70.9	60.6	17.0%
Raw Material	43.2	35.7	
Employee Expenses	7.1	6.7	
Excise duty Expenses	1.4	1.5	
Other Expenses	7.4	6.7	
Other Income	0.5	0.5	
EBITDA	12.2	10.4	17.0%
<i>EBITDA Margin</i>	<i>17.2%</i>	<i>17.2%</i>	
Depreciation	3.9	3.1	
Finance Cost	1.5	2.1	
PBT	6.9	5.2	31.2%
<i>PBT Margin</i>	<i>9.7%</i>	<i>8.6%</i>	
Tax	2.4	1.8	
PAT	4.4	3.5	27.3%
<i>PAT Margin</i>	<i>6.2%</i>	<i>5.7%</i>	
*Cash PAT	8.3	6.5	27.0%
<i>Cash PAT Margin</i>	<i>11.7%</i>	<i>10.8%</i>	

***Cash PAT includes PAT & Depreciation**

#Total Revenue includes Excise Duty


Reconciliation as per I-GAAP

Particulars in Rs. Crs	Q1FY17
Net Profit for the period as per Indian GAAP	3.2
Fair Valuation of Financial Assets - Investment in mutual funds	0.4
Adjustment on account of provision for expected credit loss	(0.1)
Re-measurement of post employment benefit obligations	(0.0)
Adjustment of borrowings at amortized cost using effective interest rate method	(0.0)
Tax Impact on above	(0.0)
Total IND-AS Adjustments	0.2
Net Profit for the period as per IND-AS	3.5
Items that will not be reclassified to profit or loss (Net of Tax)	0.0
Total Comprehensive Income (Actuarial Gain on Defined Benefit Obligation)	3.5


FY18 Road ahead




CRC Plant -Increased utilisation of the CRC plant with current orders on hand




Tooling Investment -Investing in tooling for couple of large customers. Investment expected to be recovered over part supplies in 2-3 years



Expansion Plans -Expansion of plants & consolidation of business within plants underway. Major expansion expected to be completed by Q2 FY18



Commercialisation of Home Furnishings Order - Expect to fully commercialise the Rs. 60Cr. Order by end of Q2FY18



Historical Income Statement

Particulars in Rs. Crs.	FY17	FY16	FY15	FY14	FY13
Total Revenue#	252.6	231.2	185.4	155.1	125.7
Raw Material	151.1	137.3	113.4	86.6	69.0
Employee Expenses	26.6	23.4	19.5	16.0	13.1
Excise Duty	6.2	5.6	5.7	4.3	2.9
Other Expenses	27.5	25.9	20.3	24.0	23.7
Other Income	3.4	2.8	1.6	0.5	0.6
EBITDA	44.4	41.8	28.0	24.6	17.6
<i>EBITDA Margin</i>	17.6%	18.1%	15.1%	15.9%	14.0%
Depreciation	13.3	10.3	6.4	6.0	5.6
Finance Cost	7.9	10.1	6.7	8.4	6.9
PBT	23.2	21.4	14.9	10.2	5.1
<i>PBT Margin</i>	9.2%	9.3%	8.3%	6.8%	4.1%
Tax	7.3	5.9	1.9	3.7	1.4
PAT	15.9	15.5	13.0	6.6	3.6
<i>PAT Margin</i>	6.3%	6.7%	7.2%	4.4%	2.9%
*Cash PAT	29.2	25.7	19.4	12.6	9.2
<i>Cash PAT Margin</i>	11.6%	11.1%	10.8%	8.3%	7.5%

***Cash PAT includes PAT & Depreciation**


Total Revenue includes Excise duty

Historical Balance Sheet

Rs. Crs.	FY17	FY16	FY15	FY14	FY13
Shareholder's Fund	105.6	89.8	78.3	42.6	36.0
Share capital	8.3	8.3	8.3	7.3	7.3
Reserves & Surplus	97.3	81.4	70.0	35.2	28.7
Non-current liabilities	24.6	39.1	40.6	43	19.8
Long term borrowings	16.4	30.9	32.7	38.2	15.1
Deferred Tax Liabilities (net)	6.3	6.3	5.0	3.2	3.1
Other non-current liabilities	0.9	1.2	2.0	1.9	1.6
Long-term provisions	0.9	0.8	0.8	-	-
Current liabilities	75.6	62.2	73.6	57.8	51.5
Short term borrowings	37.1	20.1	36.9	21.5	22.8
Trade Payables	19.9	18.7	15.1	27.1	18.0
Other current liabilities	15.6	19.1	19.5	9.2	10.7
Short-term provisions	3.0	4.3	2.1	-	-
Total Liabilities	205.8	191.1	192.5	143.6	107.2

Rs. Crs.	FY17	FY16	FY15	FY14	FY13
Non-current assets	107.3	102.5	87.0	58.0	50
Fixed assets	97.7	97.7	77.6	49.8	45.2
Long-term loans and advances	9.4	4.6	9.1	8.2	4.8
Non-current investments	0.2	0.2	0.3	-	-
Current assets	98.5	88.6	105.5	85.6	57.2
Current Investments	-	-	25.4	-	-
Inventories	27.5	22.5	20.1	15.2	12.5
Trade receivables	46.4	36.1	37.2	32.6	26.2
Cash and bank balances	3.7	13.2	5.9	24.5	6.6
Short-term loans and advances	20.8	16.7	16.9	13.2	11.8
Other current assets	-	0.1	-	-	0.2
Total Assets	205.8	191.1	192.5	143.6	107.1

Increasing Dividend Payouts



Particulars (Rs.)	FY15	FY16	FY17
Book Value per Share	94.3	108.2	127.2
Earning Per Share	15.6	18.6	19.1
Dividend Per share	2.0	4.0	5.0
Dividend Payout including DDT	15.3%	25.9%	31.5%

Shaily at Glance

5 Facilities
in Gujarat



100+
Injection
Moulding
Machines



950
Employees

REVENUE

3 Years
CAGR

18.6% 

EBITDA

3 Years
CAGR

29.6% 

PAT

3 Years
CAGR

10.5% 

Customer Trust & Relationships

Producing & Supplying Shellpak with zero-defect for over 2 years



I would like to express my deepest appreciation to you and the Shaily team for over 2 years of quality production to MWV, shipping over 75 million units to MWV customers!!

It is therefore with pleasure that we present this quality recognition award to Shaily...



MWV Healthcare

Producing & Supplying Knobs to GE Appliances for over 18 years



To date Shaily has provided parts to our plants at a PPM level of zero. Deliveries also are being maintained even though some of our plants have increased schedules quite unexpectedly. This has required some real dedication and customer focus on the part of Shaily.

At GE Appliances, I feel we now have a solid quality partner with Shaily Engineering



G.E. Appliances, U.S.A.

Vision & Mission

Vision

Become a USD 100 million plastics manufacturer with a Global footprint by 2020”

Mission

“ To Provide end to end solutions in plastics while delivering superior quality to our customers, higher profitability and value to our Shareholders, and Sustainability for future generations”

Pioneers in Engineering Plastics

We have to our Credit an Experience of Decades and an Expertise of manufacturing Complex Precision Components & Assemblies

Modified Vicks 5/10 gm container design to ensure leak proof in extreme climatic conditions



Pepsi Aquafina – Designed first of its kind truly tamper evident cap which has now been taken globally by Pepsi

ABB – Commercialized all Low Voltage Switchgear products in India



Sanofi Insulin pen – First innovators pen manufactured & launched from India for global markets



Offering Total Solutions in Plastics

Management

- Key Account
- Supply Chain
- Continuous Improvement

Development


- Conceptualization
- Program Management

Manufacturing

- Precision Injection Moulding
- Cleanroom Manufacturing
- Innovative Assembly
- Industrialization & Scale Up

Validation

- Pilot Testing
- Quality Management System
- Documentation



Concept to Commercialization

Catering to Fortune 100 Companies

Consumer &
FMCG



Gillette™

P&G



Pharmaceutical

WOCKHARDT | LIFE WINS



Automotive



Honeywell



Others



SIEMENS

mabe



Multiple Industry Applications



CRC Caps



FMCG




Medical



Appliances



Engineering



Automotive

State-of-the-Art Manufacturing Facilities



Rania Plant



Halol Plant



EOU Plant



Medical Devices Plant



Pharma Packaging Plant

For further information, please contact:

Company :

Shaily Engineering Plastics Ltd.
CIN – L51900GJ1980PLC065554
Mr. Sanjay Shah,
CFO & VP- Finance
sanjay@shaily.com

www.shaily.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Mr. Shogun Jain / Mr. Pratik R. Shah
shogun.jain@sgapl.net / pratik.shah@sgapl.net
+91 77383 77756 / +91 9769260769

www.sgapl.net
